• By ICR Secretariat
  • Posted Tuesday, September 20, 2022

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?


Bristol Myers Squibb's and Roche's immunotherapies have both failed to move the needle when used after surgery in early-stage kidney cancer. But the two companies’ setbacks aren’t necessarily a full relief for Merck’s rival drug Keytruda.